Thursday, September 15, 2022

Latest type 2 diabetes drug helps patients achieve blood sugar and weight targets faster

The phase 3 SURPASS trials published in 2021 established that tirzepatide lowers blood sugar and supports weight loss better than other drugs for type 2 diabetes (T2D). Now new research evaluating the time taken to reach blood glucose targets indicates that tirzepatide also helps patients achieve their blood sugar control and weight-loss goals faster than existing diabetes drugs.